QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=0F62AD57107DF9D49BFCDEB9401817EC;jsessionid=1695B1BA9C79AC59971D567D8DAC638A;jsessionid=07B881C7932148261CEE9C2D2BC9AD66;jsessionid=B37869D356F0BBA4870304131D0EC0A2;jsessionid=8F34F8044029AE02652611AC3B58E455;jsessionid=CFB398FE7E3E4CA5AE262A9FC8924038;jsessionid=EB1F0D227CD34C64D25DF916B1225632;jsessionid=85DAD1C19B3BAA003993942FF59E9082 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
3. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
4. ATXN2 is a target of N-terminal proteolysis.
5. Abnormal open states patterns in the ATXN2 DNA sequence depends on the CAG repeats length.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=0F62AD57107DF9D49BFCDEB9401817EC;jsessionid=1695B1BA9C79AC59971D567D8DAC638A;jsessionid=07B881C7932148261CEE9C2D2BC9AD66;jsessionid=B37869D356F0BBA4870304131D0EC0A2;jsessionid=8F34F8044029AE02652611AC3B58E455;jsessionid=CFB398FE7E3E4CA5AE262A9FC8924038;jsessionid=EB1F0D227CD34C64D25DF916B1225632;jsessionid=85DAD1C19B3BAA003993942FF59E9082